EMEA-001220-PIP01-11-M10 - paediatric investigation plan
baricitinib
PIPHuman
Croatian is available via eTranslation, the European Commission's machine translation service.
Translate to Croatian | Important information about machine translation
Key facts
- Invented name
- Olumiant
- Active substance
- baricitinib
- Therapeutic area
- Musculoskeletal and connective tissue disorders
- Decision number
- P/0117/2024
- PIP number
- EMEA-001220-PIP01-11-M10
- Pharmaceutical form(s)
- Oral suspension
- Film-coated tablet
- Condition(s) / indication(s)
- Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)
- Route(s) of administration
- Oral use
- Contact for public enquiries
Eli Lilly And Company Limited
Email: eu_paediatric@lilly.com
phone: +44 1256315000- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date
- Compliance check done
- Ne